Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

about

Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.

P2860

Q47793816-B416D119-E064-4191-A949-B1F1F93189F3

P2860

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

Item

http://www.wikidata.org/entity/Q38097527

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

@en

type

Item

label

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

@en

prefLabel

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

@en

P1476

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

@en

P2093

Leonardo Koeser

http://www.w3.org/2001/XMLSchema#string

P2860

Depression in multiple sclerosis: a review

Personalized medicine in multiple sclerosis: hope or reality?

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.

Natalizumab in the treatment of multiple sclerosis

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

P304

171-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERP.13.14

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul McCrone

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23570427

http://www.w3.org/2001/XMLSchema#string

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

about

P2860

P2860

Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698